Astellas confirmed this morning that the EMA has started its assessment ... options across the disease continuum.” Xtandi is currently approved in the US and Japan for the treatment of ...

Astellas confirmed this morning that the EMA has started its assessment ... options across the disease continuum.” Xtandi is currently approved in the US and Japan for the treatment of ...

The matter of the absolute schedule, if we prevail, Teva would lose FDA approval of its product ... prescribed androgen receptor antagonist enzalutamide, eventually experience resurgent disease.

Dr. Surasi started with a case of a 74 year old with mCRPC status post ADT, 6 cycles of docetaxel, enzalutamide, and palliative radiotherapy ... that Lu-PSMA radioligand therapy has been approved by ...

Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in adolescents and adult patients with Hereditary Angioedema.

President Trump's approval rating averages around 46% since taking office for his second term, with a range of 34%-49% throughout his presidency. This rating is higher than his first term average ...

The European Medicines Agency (EMA) has issued a warning about the dangers of unregulated advanced therapy medicinal products (ATMPs) being illegally offered to patients in Europe. ATMPs encompass ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

The European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for subcutaneous administration of Takeda’s Takhzyro (lanadelumab), aimed at treating hereditary ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...